AR080888A1 - Uso de un derivado de acido graso para producir una composicion oftalmica - Google Patents

Uso de un derivado de acido graso para producir una composicion oftalmica

Info

Publication number
AR080888A1
AR080888A1 ARP110101238A ARP110101238A AR080888A1 AR 080888 A1 AR080888 A1 AR 080888A1 AR P110101238 A ARP110101238 A AR P110101238A AR P110101238 A ARP110101238 A AR P110101238A AR 080888 A1 AR080888 A1 AR 080888A1
Authority
AR
Argentina
Prior art keywords
subject
program
temperature
patient
central area
Prior art date
Application number
ARP110101238A
Other languages
English (en)
Spanish (es)
Inventor
Yukihiko Mashima
Ryuji Ueno
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Publication of AR080888A1 publication Critical patent/AR080888A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
ARP110101238A 2010-04-12 2011-04-12 Uso de un derivado de acido graso para producir una composicion oftalmica AR080888A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32333810P 2010-04-12 2010-04-12
US32334210P 2010-04-12 2010-04-12
US32681110P 2010-04-22 2010-04-22
US36294510P 2010-07-09 2010-07-09
US40823710P 2010-10-29 2010-10-29

Publications (1)

Publication Number Publication Date
AR080888A1 true AR080888A1 (es) 2012-05-16

Family

ID=44798822

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101238A AR080888A1 (es) 2010-04-12 2011-04-12 Uso de un derivado de acido graso para producir una composicion oftalmica

Country Status (9)

Country Link
US (2) US20110275711A1 (enExample)
EP (2) EP2558104A4 (enExample)
JP (3) JP5686819B2 (enExample)
KR (2) KR20130099812A (enExample)
CN (2) CN102946883A (enExample)
AR (1) AR080888A1 (enExample)
CA (2) CA2795723A1 (enExample)
TW (2) TW201141486A (enExample)
WO (2) WO2011129457A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2780650A1 (en) * 2009-11-27 2011-06-03 R-Tech Ueno, Ltd. Method for screening an agent being useful for the treatment of dry eye and/or corneal and conjunctival lesion and a pharmaceutical composition obtained by the method
CN103596572A (zh) * 2011-04-12 2014-02-19 株式会社·R-技术上野 水性眼用组合物
HK1205461A1 (zh) * 2012-02-22 2015-12-18 Trustees Of Tufts College 用於眼部传输治疗剂的组合物和方法
AU2017317129B2 (en) * 2016-08-24 2020-04-30 National Institute Of Biological Sciences, Beijing Entacapone-related compounds to treat macular degeneration
US12702683B2 (en) 2019-01-03 2026-08-11 Mesoblast International Sárl Method for improving visual acuity
EP4667578A3 (en) * 2019-04-03 2026-04-01 REGENXBIO Inc. Gene therapy for eye pathologies
JP7664239B2 (ja) * 2019-10-30 2025-04-17 パフューズ セラピューティクス, インコーポレイテッド エンドセリンレセプターアンタゴニストを使用する眼疾患の処置
CA3168810A1 (en) 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases
BR112023022705A2 (pt) 2021-04-30 2024-01-16 Perfuse Therapeutics Inc Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares
WO2023283256A1 (en) 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds
AU2023303408A1 (en) 2022-07-06 2024-12-19 Aligos Therapeutics, Inc. Anti-viral compounds
FI131849B1 (en) * 2024-09-10 2026-01-09 Pixieray Oy METHOD AND OPTICAL DEVICE FOR MONITORING THE USE OF EYE DROPS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU771130B2 (en) * 2000-01-18 2004-03-11 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
WO2003020283A2 (en) * 2001-08-29 2003-03-13 Novartis Ag Method for treating diabetic retinopathy
JP5222462B2 (ja) * 2003-08-21 2013-06-26 スキャンポ・アーゲー 眼科用組成物
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
US20080233053A1 (en) * 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
US20100087540A1 (en) * 2008-10-07 2010-04-08 R-Tech Ueno, Ltd. Pharmaceutical composition

Also Published As

Publication number Publication date
EP2558103A4 (en) 2013-09-25
WO2011129461A1 (en) 2011-10-20
CA2795723A1 (en) 2011-10-20
US20110275715A1 (en) 2011-11-10
US20110275711A1 (en) 2011-11-10
JP2013528563A (ja) 2013-07-11
KR20130050939A (ko) 2013-05-16
JP2013523601A (ja) 2013-06-17
CN102946883A (zh) 2013-02-27
KR20130099812A (ko) 2013-09-06
EP2558104A4 (en) 2013-12-11
JP5686819B2 (ja) 2015-03-18
TW201204366A (en) 2012-02-01
EP2558104A1 (en) 2013-02-20
EP2558103A1 (en) 2013-02-20
JP5878128B2 (ja) 2016-03-08
TW201141486A (en) 2011-12-01
JP2016026182A (ja) 2016-02-12
CA2795720A1 (en) 2011-10-20
WO2011129457A1 (en) 2011-10-20
CN102933217A (zh) 2013-02-13

Similar Documents

Publication Publication Date Title
Benito et al. Objective optical assessment of tear-film quality dynamics in normal and mildly symptomatic dry eyes
Colak et al. Comparison of corneal topographic measurements and high order aberrations in keratoconus and normal eyes
Pinero et al. Ocular scattering
Wolsley et al. Investigation of changes in the myopic retina using multifocal electroretinograms, optical coherence tomography and peripheral resolution acuity
Low et al. The outcomes of primary pediatric keratoplasty in Singapore
BR112013021153A2 (pt) dispositivo e métodos de rastreamento ocular de fotorrefração
León et al. A comparison of the reliability of dynamic retinoscopy and subjective measurements of amplitude of accommodation
MX2021014958A (es) Sistema y metodo para prueba multimodal de enga?o calificado por aprendizaje de maquina.
Dysli et al. Fluorescence lifetime imaging in retinal artery occlusion
Read Ocular and environmental factors associated with eye growth in childhood
Loreck et al. Morning myopic shift and glare in advanced Fuchs endothelial corneal dystrophy
Chakraborty et al. Diurnal variations in ocular aberrations of human eyes
Hilmi et al. Measurement of contrast sensitivity using the M&S Smart System II compared with the standard Pelli–Robson chart in patients with primary pterygium
Qiao et al. Full-field strain mapping for characterization of structure-related variation in corneal biomechanical properties using digital image correlation (DIC) technology
Aldossari et al. Effect of accommodation on peripheral eye lengths of emmetropes and myopes
Hussein et al. The long-term outcomes in children who are not compliant with spectacle treatment for accommodative esotropia
Arranz-Márquez et al. Disminución de la agudeza visual
Gillmann et al. Relationship between contact lens sensor output parameters and visual field progression in open-angle glaucoma: assessment of a practical tool to guide clinical risk-assessment
Ortiz et al. Quantification and monitoring of visual disturbances for patients with cataracts using Halo v1. 0 software.
ES2441669A1 (es) Método para la detección de pérdidas de función visual.
Benzoni et al. Does the dynamic cross cylinder test measure the accommodative response accurately?
Yeh et al. The genetic effect on refractive error and anterior corneal aberration: twin eye study
O'Connell et al. Provocative intraocular pressure challenge preferentially decreases venous oxygen saturation despite no reduction in blood flow
Hassan et al. correlation of age with central corneal thickness and corneal endothelial cell density in Pakistani population
RU2553926C1 (ru) Способ прогнозирования эффективности плеоптического лечения у детей и подростков с амблиопией

Legal Events

Date Code Title Description
FB Suspension of granting procedure